Sheaff Brock Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,535	Closed	-$516K	–	557
2022 Q4	$516K	Hold	4,535	–	–	0.05%	247
2022 Q3	$281K	Sell	4,535 -2,031	-31%	-$142K	0.03%	347
2022 Q2	$524K	Buy	6,566 +89	+1%	+$8.43K	0.04%	239
2022 Q1	$681K	Buy	6,477 +581	+10%	+$56.6K	0.05%	228
2021 Q4	$636K	Buy	5,896 +1,664	+39%	+$182K	0.04%	237
2021 Q3	$464K	Hold	4,232	–	–	0.03%	282
2021 Q2	$397K	Buy	4,232 +32	+0.8%	+$2.94K	0.03%	309
2021 Q1	$386K	Hold	4,200	–	–	0.03%	298
2020 Q4	$307K	Buy	+4,200	New	+$312K	0.03%	333
2017 Q3	–	Sell	-10,500	Closed	-$125K	–	634
2017 Q2	$125K	Buy	10,500 +500	+5%	+$6.22K	0.02%	561
2017 Q1	$148K	Buy	+10,000	New	+$162K	0.02%	539

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sheaff Brock Investment Advisors's HZNP Position: Q1 2023 in Review

Sheaff Brock Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 4,535 shares — an estimated $516K sold.

Sheaff Brock Investment Advisors first reported a position in HZNP in Q1 2017 and held it in 11 quarters. The position peaked at $681K in Q1 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Sheaff Brock Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Sheaff Brock Investment Advisors sold 4,535 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $516K.
Sheaff Brock Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017 and held it in 11 quarters.
Sheaff Brock Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $681K in Q1 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Sheaff Brock Investment Advisors's 13F filing for Q1 2023, filed 1 May 2023.